Kornimate/medical-research-clean huggingface dataset:
corneal flap transplantation for macular hole repair of high myopia

Conditions: Retinal Perforations; Myopia, Degenerative

Summary: the goal of this clinical trial is to learn about an innovative surgical technique for macular hole repair. this technique is for patients with high myopia using pars plana vitrectomy (ppv) combined with corneal flap transplantation. the main questions it aims to answer are: * is the innovative surgical technique useful for patients? * is the surgical technique safe for patients? participants will: * undergo ppv combined with corneal flap transplantation to cover the macular hole. * maintain a prone position for 2 weeks postoperatively. * be observed by visual acuity, slit lamp, optical coherence tomography (oct) and fundus photography for 1 year after surgery.

we describe an innovative surgical technique for macular hole repair using pars plana vitrectomy (ppv) combined with corneal flap transplantation. the corneal flap was sealed with autologous blood. the vitreous cavity was then filled with perfluoropropane (c3f8) or sterile air.

Eligibility criteria:
inclusion criteria: * patients with macular hole and retinal detachment caused by pathologic myopia. exclusion criteria: * patients with previous retinal surgery, trauma, other ocular diseases that could affect the vision, for example choroidal neovascularization, diabetic retinopathy, or opaque corneas were excluded.

Keywords: corneal flap transplantation femtosecond laser small incision lenticule extraction macular hole surgical technique
effect of a new high-protein oral supplement on functional parameters in patients in nursing homes

Conditions: Malnutrition

Summary: the objective of this study is to determine whether a supplementation with a new high-protein oral supplement can improve the evolution of functional parameters in elderly patients in nursing homes.


Eligibility criteria:
inclusion criteria: * man or woman aged more than 60 years old * living in a nursing home for at least 2 months * malnourished or at risk of malnutrition (mna\<23.5 or bmi\<24 or albumin\<35 g/l or weight loss of more than 5 kg in the last 6 months) * without dementia or with moderate dementia (mmse \> or =10/30) * able to walk without human assistance (technical assistance allowed) * no vitamin d supplementation * able to follow the study procedures and agreed to consume oral supplement exclusion criteria: * severe dementia (mmse \< 10/30) * enteral nutrition * severe renal or hepatic impairment * cancer with chemotherapy * uncontrolled diabetes * lactose intolerance * cow's milk protein allergy

Keywords: elderly nursing home functional impairment high-protein oral supplement
a trial of plerixafor/g-csf as additional agents for conditioning before tcr alpha/beta depleted hsct in was patients

Conditions: Wiskott-Aldrich Syndrome; Hematopoietic Stem Cell Transplantation; Graft Failure

Summary: treatment study to assess of safety and efficiency of conditioning with plerixafor and g-csf as additional agents for prevention of graft failure after transplantation with tcr alpha/beta grafts depletion in patient with wiskott-aldrich syndrome.

severe graft dysfunction, such as the degree of donor chimerism predominantly in the myeloid compartment is one of major problem in patients with wiskott-aldrich syndrome (was), especially after hematopoietic stem cell transplantation (hsct) from alternative donor. it often leads to the development of severe thrombocytopenia or even transplants rejection. in this study the hypothesis is that the use of plerixafor and g-csf as additional agents in conditioning regimen would offers advantages due to lowing risk of mixed chimerism after hsct. this effect is based on the fact that simultaneous use of plerixafor with g-csf is efficient in inducing stem cell release and opening of bone marrow (bm) niches. moreover, stem cell release probably leads to liberation of host stem cells from the anti-apoptotic effects of the bm stroma for the more powerful effect of chemotherapy. in this study, the investigators use tcr alpha/beta grafts depletion of the grafts as basic technology for hsct from haploidentical and unrelated donors approved in institution. thus, the purpose of this study is to evaluate the safety and efficiency of myeloablative conditioning with plerixafor and g-csf as additional agents for prevention of graft failure after transplantation with tcr alpha/beta grafts depletion in patients with wiskott-aldrich syndrome.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 1 months and \< 19 years * patients diagnosed with wiskott-aldrich syndrome eligible for an allogeneic transplantation and lacking a related hla-matched donor * lansky/karnofsky score \> 40, who \> 4 * signed written informed consent exclusion criteria: * dysfunction of liver (alt/ast \> 5 times normal value, or bilirubin \> 3 times normal value), or of renal function (creatinine clearance \< 30 ml / min) * severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction \<40%) * serious concurrent uncontrolled medical disorder * lack of parents' informed consent.
study of mometasone furoate/formoterol fumarate inhalation combination in healthy volunteers

Conditions: Healthy

Summary: this study will compare the performance of three combination metered dose inhalation devices and the variability of mometasone and formoterol doses delivered to the lungs in a healthy volunteer population


Eligibility criteria:
inclusion criteria: * healthy, male or female subjects age 18 to 65 years of age (included) * in good health as confirmed by past medical history * female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 2 years) * body mass index (bmi) within the range of 18.5 to 32 kg/m2 and weigh at least 50 kg * able to communicate well with the investigator, to understand and comply with the requirements of the study * understand and sign the written informed consent exclusion criteria: * smokers (use of tobacco products in the previous 1 year with a pack year history of no greater than 10 pack years). * female subjects who are pregnant, or lactating * treatment with any oral or intravenous corticosteroids within 1 month of the first study treatment. * patients with a current respiratory tract infection or one within 1 month prior to screening. * patients with a history of malignancy, myocardial infarction, untoward reactions to sympathomimetic amines or inhaled medicine. subjects with a current or history of a clinically significant cardiac arrhythmia. * participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. * donation or loss of 400 ml or more of blood within 8 weeks prior to dosing. * significant illness within the two weeks prior to dosing. * a past medical history of clinically significant ecg abnormalities. * history of fainting, known hypersensitivity to the study drug or drugs similar to the study drug. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study, immunocompromise, including a positive hiv (elisa and western blot) test result, positive hepatitis b surface antigen (hbsag) or hepatitis c test result, drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening evaluations. other protocol-defined inclusion/exclusion criteria may apply

Keywords: dose proportionality pharmacokinetics mometasone formoterol healthy volunteers study
combined approach to resection of glioblastoma (gbm) by 5-aminolevulinic acid (5-ala) and intraoperative magnetic resonance imaging (mri)

Conditions: Glioblastoma

Summary: in the treatment of glioblastoma (gbm) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. at the same time eloquent areas of the brain have to remain intact to preserve quality of life. both 5-ala fluorescence and intraoperative mri are used for intraoperative marking of tumor tissue and thereby to improve precision of gbm-resection. we now study whether the combination of 5-ala fluorescence and intraoperative mri increases the number of sites where tumor tissue can be detected. - trial with surgical intervention

precision of gbm-resection intraoperative marking of tumor tissue combination of 5-ala fluorescence and intraoperative mri

Eligibility criteria:
inclusion criteria: * patients with glioblastoma multiforme (gbm) * no other tumor types or metastases exclusion criteria: * allergy against 5-ala or porphyrin * porphyria * pregnancy
establishment of risk factors model of drug-induced coagulation disorder caused by cefoperazone sulbactam sodium

Conditions: Risk Factors

Summary: the incidence rate of drug-induced blood diseases accounts for about 10% of all drug-induced diseases, most of which are serious at the time of onset, and the mortality rate can be as high as 32.5%. in this study, cefoperazone sulbactam sodium, which is commonly used in clinic, was selected as the target drug, and the epidemiological characteristics of drug-induced coagulation dysfunction and the construction of risk factor models were studied by single factor and multiple factor logistic regression analysis.

investigators selected inpatients from qianfoshan hospital of shandong province from january 1, 2018 to december 30, 2021, extracted the cohort according to the inclusion and exclusion criteria, and divided it into exposure group and control group to find out the risk factors of cefoperazone sulbactam sodium causing coagulation disorders, and build a risk factor model of drug-induced coagulation disorders caused by cefoperazone sulbactam sodium.

Eligibility criteria:
inclusion criteria: all inpatients who used cefoperazone sulbactam sodium during hospitalization; * hospital stay ≥ 48h * age ≥ 18 years old exclusion criteria: * age \< 18 years * severe liver and kidney dysfunction * patients with vitamin k deficiency * patients with hematological diseases * patients with advanced malignant tumor or mental disease * patients with incomplete clinical data

Keywords: coagulation disorder epidemiological study risk factors building models
patient perceptions around quality of care through telemedicine in neuro-oncology

Conditions: Central Nervous System Neoplasm; Leptomeningeal Neoplasm; Metastatic Malignant Neoplasm in the Brain; Primary Brain Neoplasm

Summary: this study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.

primary objective: i. to evaluate the patient-perceived quality of care by group (telemedicine versus in-person visits) in patients with central nervous system (cns) cancer. secondary objectives: i. to characterize the visits provided by telemedicine compared to those in-person. ii. to contrast the average time spent on telemedicine visits compared to in-person visits, and the delay between visit order placement and visit occurring. iii. to evaluate the domains of patient care addressed on a telemedicine visit versus in-person visit per documentation, including (1) treatment planning, (2) symptom burden, (3) goals of care. iv. to evaluate frequency of acute care sought (through emergency room or urgent care clinic) within 30 days of encounter in telemedicine visit versus (vs) in-person visit. v. the impact of patient and clinical characteristics on perceived quality of care in the context of covariate-adjusted modeling. outline: patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.

Eligibility criteria:
inclusion criteria: * patients with a cns tumors: this includes patients with primary brain tumors, brain metastases, and leptomeningeal disease * established patients with a follow up encounter with neuro-oncology at the brain and spine center at the university of texas md anderson cancer center; this encounter can be * an in-person visit * a telemedicine appointment exclusion criteria: * encounter occurred with the assistance of official language translation support * patients with telephone encounters (without interactive video) * new patient or consult visits * neither patient nor caregiver present during the visit are available or able to answer survey questions
effect of early analgesia with erector spinae plane block to reduce ventilation after severe chest trauma

Conditions: Severe Chest Trauma

Summary: blunt chest trauma is commonly associated with rib fractures and early pain management is a key goal after chest trauma. in spontaneous breathing patients, pain limits coughing efficiency and secretion clearance, thereby potentially leading to progressive atelectasis, loss of functional residual capacity (frc) and, ultimately, respiratory distress. in patients under mechanical ventilation, pain interacts with the weaning of mechanical ventilation inducing an increase of the duration of invasive ventilation. according to recent french guidelines for chest trauma management, immediate analgesia is initially performed by intravenous multimodal analgesia followed by a thoracic epidural analgesia or a paravertebral block if the pain is not controlled within the first 12 hours. however, these blocks necessitate an experienced anaesthesiologist, are at risk of severe complications and are contraindicated in case of post-traumatic coagulopathy. all these considerations limit their indication in the trauma bay. the erector spinae plane (esp) block is an easy to perform, ultrasound guided, regional anaesthesia for pain management after thoracic surgery. this block can be made continuously with a dedicated catheter for a continuous infusion of local anaesthetic drug with boli. the esp block is performed by depositing the local anaesthetic in the fascial plane, deeper than the erector spinae muscle at the tip of the transverse process of the vertebra. this block is less invasive with fewer contraindications as compared to epidural analgesia or paravertebral blocks. after chest trauma, esp block was associated with an improvement in respiratory capacity in a retrospective study. however, there is no randomised control trial assessing esp efficacy. our hypothesis is that early continuous esp block in the trauma bay decreases the number of days with invasive and/or non-invasive ventilation after chest trauma.


Eligibility criteria:
inclusion criteria: age \> 18 years blunt chest trauma with 3 or more rib fractures on thoracic ct scan with spontaneous breathing or under mechanical ventilation in the trauma bay requiring an intensive (or intermediate) care unit admission exclusion criteria: pre-hospital cardiac arrest patient not expected to survive within the first 72 hours uncontrolled haemodynamic instability despite initial resuscitation (systolic arterial blood pressure lower than 90 mmhg at the time of catheter insertion) mechanical ventilation for severe traumatic brain injury (abbreviated injury score, ais, head \> 2) spinal cord injury at the cervical or thoracic levels hypovolaemia. hypersensitivity to ropivacaine or other amide-bound local anaesthetics subject in exclusion period of another interventional study pregnant, breastfeeding women

Keywords: chest trauma erector spinae plane block pain management
a safety and efficacy study of ns2 in patients with anterior uveitis

Conditions: Non-infectious Anterior Uveitis

Summary: this is a randomized, multi-center, investigator masked, comparator controlled study. the purpose of this study is to determine the efficacy and safety of ns2 in patients with non-infectious acute anterior uveitis. subjects will be randomized 1:1:1 to receive multiple doses of ns2 0.5%, ns2 0.5% and pred forte® 1%, or pred forte® 1%. free aldehydes are thought to be related to inflammatory diseases such as uveitis. ns2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.


Eligibility criteria:
inclusion criteria: * non-infectious anterior uveitis * grade 1 - grade 3 anterior chamber cell count * subjects must have intraocular pressure \<25 mmhg at baseline and may only administer a maximum of 1 topical medication to control intraocular pressure in the study eye. * visual acuity ≥ 20/200 in the study eye exclusion criteria: * severe/serious ocular pathology * active intermediate or posterior uveitis. * previous anterior uveitis episode in the study eye within 4 weeks of visit 1 * oral corticosteroids within 14 days of visit 1 * intravitreal or sub-tenon corticosteroid treatment in the study eye within the past 6 months.

Keywords: uveitis acute uveitis anterior uveitis ns2 aldeyra prednisolone acetate
effects of a probiotic on oral microbiota and glycemic control in type 2 diabetics; a randomized clinical trial

Conditions: Diabetes Mellitus,Type 2; Periodontitis

Summary: the present study evaluated clinically the effects of a probiotic on oral microbiota and glycemic control in t2 diabetic patients with periodontal disease. the study was designed as a prospective randomized, double-blind, placebo- controlled interventional study. at baseline and at the end of the 30 day- probiotic period, all clinical, microbiological, and biochemical measurements were tested. colony counts of oral microbiota, blood fructosamine levels and crp were the outcomes of the study.

objectives: to investigate the effects of an oral probiotic use, containing 4 billion colony forming unit (cfu/g) streptococcus salivarius m18 strain (dentoblis™), on the quantities of oral microbiota in saliva and metabolic markers of t2 diabetics such as fructosamine, c-reactive protein (crp). materials and methods: the trial was designed as a prospective randomized, double-blind, placebo- controlled interventional study. participants were selected from type 2 diabetics with periodontitis and aged 30-65 years, who presented to the diabetic center in istanbul. totally 70 patients were randomly assigned to probiotic or placebo groups. at baseline and at the end of the 30 day-probiotic period, colony counts of oral microbiota and biochemical measurements of diabetes were assessed.

Eligibility criteria:
inclusion criteria: * being diagnosed with t2 diabetes with \<10% hba1c for at least 6 months, * 30-65 years old patients, * high caries activity patients with periodontal disease index (pdi) scores of 2, 3, 4 and 5, * provision of written informed consent - exclusion criteria: * patients regularly using probiotics, * patients on corticosteroid, non-steroid anti-inflammatory, antibiotic or antibacterial mouthwash therapy, * patients with multi-organ deficiency such as liver or kidney failure, * patients with immunodeficiency syndrome or on immunosuppressive therapy, * patients with heart valve prosthesis or central venous catheter, * patients undergoing chronic or acute disease therapy such as cancer, arthritis, influenza, flu, * legal incapability or mental incapacity to give consent.

Keywords: probiotics diabetes mellitus oral microbiota periodontitis streptococcus salivarius m18
mscs for the treatment of burn wounds

Conditions: Burn Wound; Second- or Third-degree Burn

Summary: the goal of this study is to evaluate the capacity of allogenic mesenchymal stromal cells form bone marrow (bm-msc) or adipose tissue(ad-msc) to induce wound healing in patients with burn wounds.

based on the paracrine and immunomodulatory effects of mscs, they are considered promising cells for tissue engineering and skin regeneration in burn wounds. this protocol is designed to evaluate the efficacy of transplantation of allogenic bm-mscs or ad-mscs, included in preclotted platelet-rich plasma (prp), in patients with deep- or full-thickness burns (second- or third-degree / ab b or b degree). all patients will receive concomitant first-line treatments.

Eligibility criteria:
inclusion criteria: * age between 2 weeks and 85 years old * patient with second- or third-degree burn (ab/b or b). * thermal burns * electrical burns * chemical burns * informed consent of the patient or caretaker exclusion criteria: * first degree burn (a or ab) * evidence of active infection at the wound site * chronic malnutrition * systemic inflammatory response syndrome (sirs) or sepsis * moderate or severe respiratory tract or lungs burn injuries * autoimmune disease (e.g. multiple sclerosis, lupus erythematosus) * severe pulmonary disease, hematologic disease, malignancy, or hypo-immunity. * diabetes * pregnancy

Keywords: burn wounds, skin regeneration, mscs
cognitive functional therapy versus exercises for chronic shoulder pain

Conditions: Chronic Shoulder Pain

Summary: the objective of this clinical trial is to determine whether cognitive functional therapy is superior to therapeutic exercises for the treatment of chronic shoulder pain. the main questions it aims to answer are: is cognitive functional therapy superior to therapeutic exercises for pain and disability in individuals with chronic shoulder pain? is cognitive functional therapy superior to therapeutic exercises for functionality and psychosocial factors? participants will: receive 4 to 8 sessions of cognitive functional therapy once a week for four to eight weeks. follow a therapeutic exercise protocol for eight weeks with a frequency of twice per week.

this will be a randomized controlled trial, single-blind, with two parallel groups. 148 individuals with chronic shoulder pain will be randomly assigned to one of two groups: cognitive functional therapy (cft) or therapeutic exercises. the interventions will last between four and eight weeks, with the cft group receiving therapy once a week and the therapeutic exercise group receiving sessions twice a week for eight weeks. the primary outcomes will be pain intensity and disability, while the secondary outcomes will include specific function, kinesiophobia, self-efficacy, sleep quality, treatment expectations, perception of change, treatment satisfaction and exercise adherence.

Eligibility criteria:
inclusion criteria: individuals of both sexes, aged between 18 and 65 years, will be included if they have had shoulder pain for at least 3 months and report a pain intensity of at least 3 points on the numeric pain rating scale (nprs) at rest or during arm movement. additionally, they must have a minimum score of 20 points on the shoulder pain and disability index (spadi). exclusion criteria: individuals will not be included if they have adhesive capsulitis, defined as a loss of more than 50% of passive shoulder range of motion in external rotation; previous shoulder surgery; a history of shoulder fracture; systemic musculoskeletal diseases (e.g., rheumatoid arthritis, fibromyalgia); shoulder pain reproduced by active or passive cervical spine movement; signs of glenohumeral instability identified by a positive sulcus test or a positive apprehension test indicating laxity in the glenohumeral joint; self-reported systemic disease; a positive drop arm test; pregnancy; active cancer treatment; neurological diseases; cognitive impairments; corticosteroid injection within three months prior to the intervention; or physical therapy in the three months preceding the study. participants will be discontinued from the study if they experience fractures, surgeries, musculoskeletal or neural injuries that prevent access to treatment, or receive corticosteroid injections during the treatment or follow-up period.

Keywords: shoulder pain psychosocial rehabilitation exercise therapy